Australia's most trusted
source of pharma news
Friday, 12 December 2025
Posted 4 September 2025 PM
ASX-listed Argenica took a pummelling when it released its latest trial results which showed no overall treatment effect across the broad population.
Shares fell 64.2 per cent after a three-day trading halt was lifted with the publication of topline Phase 2 trial results of its flagship product ARG-007 in acute ischemic stroke (AIS) patients, showing no overall treatment effect compared to a placebo.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.